Table 1.
Study characteristics of included studies.
| Study Year | Country | Study Design | Gender (Male/Female) | Number of Procedures | DEB-TACE | C-TACE | Age † (Years) | Length of Stay (Months) |
|---|---|---|---|---|---|---|---|---|
| Dhanasekaran et al., 2010 | USA | Case–control | 54/17 | 71 | 45 | 26 | 59.6 ± 12.1 | 3–6 |
| Kloeckner et al., 2015 | Germany | Case–control | 212/38 | 250 | 76 | 174 | NR | 18 |
| Wiggermannet al., 2011 | Germany | Case–control | 37/7 | 44 | 22 | 22 | 70.3 ± 7.1 | 1.5–2 |
| Nicolini et al., 2013 | Italy | Case–control | 34/4 | 38 | 22 | 16 | 56.5 ± 6.5 | NR |
| Scartozzi et al., 2010 | Italy | Case–control | 122/28 | 150 | 87 | 63 | 69 (40–89) | NR |
| Arabi et al., 2015 | KSA | Case–control | 39/16 | 76 | 51 | 25 | 67 | 3 |
| Song et al., 2012 | South Korea | Case–control | 90/39 | 129 | 60 | 69 | 60.5 ± 10.6 | 18 |
| Kucukay et al., 2015 | Turkey | Case–control | 103/23 | 126 | 53 | 73 | 63.8 ± 10.9 | 12 |
| Frenette et al., 2014 | USA | Case–control | 91/20 | 111 | 35 | 76 | 59.2 ± 7.9 | NR |
| Hui Liet al., 2019 | China | Cohort | 70/11 | 81 | 42 | 39 | 57.1 ± 14.1 | 15 |
| Ganget al., 2017 | China | Cohort | 36/6 | 42 | 22 | 20 | NR | 6 |
| Wenet al., 2019 | China | Cohort | 99/21 | 120 | 52 | 68 | 58.9 ± 12.1 | NR |
| Facciorusso et al., 2015 | Italy | Cohort | 197/52 | 249 | 145 | 104 | 67 (67–93) | 42 |
| Recchia et al., 2012 | Italy | Cohort | 75/30 | 105 | 35 | 70 | 71 (47–80) | 14 |
| Morimoto et al., 2016 | Japan | Cohort | 78/27 | 105 | 50 | 55 | 72.4 ± 9.7 | 19 |
| Petruzzi et al., 2013 | USA | Cohort | 51/12 | 63 | 33 | 30 | 64 (25–82) | 9.6 |
| Soo Lee et al., 2016 | South Korea | Cohort | 89/19 | 108 | 54 | 54 | 63.3 ± 10.4 | 36.8 |
| Lee et al., 2016 | South Korea | Cohort | 204/46 | 250 | 144 | 106 | 62 (30–90) | NR |
| Puchol et al., 2011 | Spain | Cohort | NR | 72 | 47 | 25 | 69.3 ± 11.8 | 1. |
| Monier et al., 2016 | Switzerland | Cohort | 113/18 | 131 | 74 | 57 | 64.2 ± 11.8 | 27 ± 23 |
| Elshahat et al., 2015 | Egypt | Cohort | 40/20 | 60 | 34 | 26 | 61.1 (32–81) | 6 |
| Massani et al., 2017 | Italy | Cohort | 69/13 | 82 | 28 | 54 | 68.3 ± 11.3 | 12 |
| Rahman et al., 2016 | Malaysia | Cohort | 62/17 | 79 | 45 | 34 | 62 ± 11 | 11.8 |
| Van et al., 2011 | Europe | RCT | 25/5 | 30 | 16 | 14 | 62.3 ± 12.6 | 1.5 |
| Vogl et al., 2011 | Germany | RCT | 185/27 | 212 | 102 | 110 | 67.0 ± 9.2 | 6 |
| Lammer et al., 2010 | Germany | RCT | 174/27 | 201 | 93 | 108 | 67.3 ± 9.1 | 6 |
| Golfieri et al., 2014 | Italy | RCT | 135/42 | 177 | 89 | 88 | 68.6 ± 8.0 | 24 |
| Sacco et al., 2011 | Italy | RCT | 45/22 | 67 | 33 | 34 | 70 ± 7.7 | 26.8 ± 12 |
| Bargellini et al., 2021 | Italy | Cohort | 163/39 | 202 | 101 | 101 | 62.7 ± 10.8 | 2.5 ± 2.3 |
| Fan et al., 2021 | China | Cohort | 107/12 | 119 | 57 | 62 | 50 ± 11 | 6 (4–8) * |
| Zhang et al., 2021 | China | Cohort | 871/131 | 1002 | 394 | 608 | 60 ± 13 | NR |
| Chiu et al., 2020 | Taiwan | Cohort | 50/11 | 61 | 42 | 19 | 65 (27–87.6) | NR |
| Shimose et al., 2020 | Japan | Cohort | 111/63 | 174 | 76 | 98 | 73 (51–91) | NR |
| Wu et al., 2018 | China | Cohort | 49/5 | 54 | 24 | 30 | 55.2 ± 8.5 | NR |
† Age reported as mean ± SD where indicated. * Length of stay reported as days where indicated. Abbreviations: C-TACE: conventional transcatheter arterial chemoembolization; DEB-TACE: drug-eluting beads transcatheter arterial chemoembolization; KSA: Kingdom of Saudi Arabia; NR: not reported; RCT: randomized controlled trial; USA: United States of America.